Corvus Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Corvus Pharmaceuticals, Inc. (CRVS) on October 28, 2022, regarding an event dated October 25, 2022. The Company is a Delaware corporation with its principal executive offices in Burlingame, California, and its common stock trades on the Nasdaq Global Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report addresses a regulatory listing status issue rather than financial performance results.
Material Changes
On October 25, 2022, the Company received written notice from Nasdaq staff that its common stock failed to maintain the minimum bid price of $1.00 per share for 30 consecutive business days (September 12, 2022, through October 24, 2022), violating Nasdaq Listing Rule 5450(a)(1).
Outlook, Risks, and Contingencies
- Compliance Period: The Company has 180 calendar days, until April 24, 2023, to regain compliance. To do so, the closing bid price must be at least $1.00 per share for a minimum of ten consecutive business days prior to the compliance date.
- Secondary Compliance Option: If the Company fails to regain compliance by April 24, 2023, it may be eligible for an additional 180-day period. This requires transferring its listing to the Nasdaq Capital Market and meeting all applicable initial listing standards for that market, except the minimum bid price requirement.
- Remedial Actions: The Company may consider effecting a reverse stock split to cure the deficiency, subject to Nasdaq's determination of feasibility.
- Delisting Risk: If the Company cannot cure the deficiency or meet other listing standards, Nasdaq may issue a delisting notice. The Company retains the right to appeal such a determination to a Nasdaq Hearing Panel, though success is not assured.
Investor Verification Checklist
- Monitor the daily closing bid price of CRVS common stock to track progress toward the $1.00 threshold.
- Review future filings for announcements regarding a potential reverse stock split or transfer to the Nasdaq Capital Market.
- Verify the Company's status regarding the April 24, 2023, compliance deadline.
- Check for any subsequent correspondence from Nasdaq regarding the Company's ability to cure the deficiency.